USFDA grants FTD to efanesoctocog alfa for hemophilia A treatment

Efanesoctocog alfa represents a new class of factor VIII replacement therapies and can potentially transform factor replacement therapy for patients suffering from hemophilia A. Credit: JOSHUA COLEMAN/Unsplash